Oncolytics Biotech issued new U.S. patent

Oncolytics Biotech Inc. has announced that it has been granted U.S. Patent 7,252,817 entitled "Viruses for the Treatment of Cellular Proliferative Disorders."

The claims cover the use of modified herpes simplex viruses (HSV) to treat cellular proliferative disorders which include neoplasias (cancers). "This patent expands our intellectual property portfolio in viruses other than reovirus," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics.



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment